Clinical Trial Update: Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia [Phase 3]

View source ↗

Summary

Phase 3 trial investigating hydroxyurea for prevention of organ damage in children with sickle cell anemia; trial completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Hematologic Diseases, Anemia, Sickle Cell | Phase 3 | Status: COMPLETED | Results posted: 2020-08-19